Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, bortezomib, and dexamethasone versus daratumumab, bortezomib, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-7): results from a phase 3, open-label, randomised controlled trial

Lancet Haematol

Hungria V, Hus M, Fu C, Zherebtsova V, Ward C, Ho PJ, Mikulski D, Muronova L, Cerchione C, Loubert A, Bunod L, M'Hari M, Pirooz N, Rogers R, Lin CP, Roy-Ghanta S, Opalinska JB, Purser M, McKeown A, McNamara S, Baig H, Eccersley L, Pompilus F, Mateos MV, DREAMM-7 trial study group

doi: 10.1016/S2352-3026(25)00163-2

Multiple Myeloma (MM)

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial

Lancet Haematol

Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S, DREAMM-8 investigators

doi: 10.1016/S2352-3026(25)00256-X

Breast Cancer

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

Ann Oncol

Mayer EL, Bidard FC, Park YH, Janni W, Ma C, Cristofanilli M, Iwata H, Bianchini G, Kalinsky K, Chia S, Brufsky A, Fasching PA, Nowecki Z, Chen SC, Pascual J, Moreau L, Ruiz-Borrego M, Shai A, Karadurmus N, Sohn JH, Zhu Y, Leddin I, Miralles MS, Bartlett CH, Turner N

doi: 10.1016/j.annonc.2025.10.006

Myelodysplastic syndromes

Clinical outcomes of patients with lower risk myelodysplastic syndrome from EUMDS registry eligible for transplantation: Implications for transplantation strategies

Br J Haematol

Savic A, Taylor A, Fenaux P, Symeonidis A, Cargo C, Mittelman M, Petzer V, Sanz G, Čermák J, Langemeijer S, Hellström-Lindberg E, Comont T, D'Aveni M, Culligan D, Kotsianidis I, Panagiotidis P, van Marrewijk C, Smith A, Crouch S, de Witte T, Malcovati L, EUMDS registry

doi: 10.1111/bjh.70384

Further Publications

International Consensus-Driven Recommendations for Patient-Reported Outcome Research Objectives in Early Phase Dose-Finding Oncology Trials: OPTIMISE-ROR

J Clin Oncol

Alger E, Aiyegbusi OL, Dueck AC, Minchom A, Pe M, Peipert JD, Snyder C, Symeonides SN, Wilson R, Basch E, Qiao Y, Bates SE, Bulbeck H, Dean L, Di Maio M, Hansen AR, Kholmanskikh O, Kobayashi K, Landers D, Le Tourneau C, Lee JJ, Ma BBY, Marshall LV, Patel S, Petrie J, Pond GR, Prior K, Rantell KR, Reeve JF, Solovyeva O, Wages NA, Weber HA, Calvert MJ, Yap C

doi: 10.1200/JCO-25-01625

Breast Cancer

Patient-reported outcome thresholds and their associations with survival, adverse events, and quality of life in a pooled analysis of breast cancer trials

Int J Cancer

Menz BD, Modi ND, Abuhelwa AY, Kuderer NM, Lyman GH, Swain SM, Kichenadasse G, Shahnam A, Haseloff M, Vitry A, Rammant E, Ramsey I, Chan RJ, McKinnon RA, Rowland A, Sorich MJ, Hopkins AM

doi: 10.1002/ijc.70020

RECOMMENDED

Lung, Respiratory and Thoracic Cancer

Real-world outcomes versus clinical trial results of first-line immunotherapy with or without chemotherapy in patients with metastatic non-small-cell lung cancer: the CORRELATE study

★ 1 Recommended by Dr Marcus Hesse, Faculty Member

ESMO Open

Peters S, Salomonsen RJ, Diaz Perez I, Shcherbakova T, Wang A, Cai L, Sadow S, Liu SV

doi: 10.1016/j.esmoop.2025.106031

Further Publications

Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial

Lancet Oncol

Wintner LM, Sztankay M, Abdel-Razeq H, Hamdan-Mansour R, Caocci G, Mouillet G, Kikawa Y, Shibata N, Krishnamurthy MN, Joshi A, Krishnatry R, Jain A, Pappot H, Petranović D, Trobentar A, Schmidt H, Schulze S, Tararykova A, Zabernigg A, Giesinger JM, Holzner B, EORTC Quality of Life Group

doi: 10.1016/S1470-2045(25)00679-5

Lymphoma

Impact of immunochemotherapy regimens on outcomes of patients with primary mediastinal B-cell lymphoma in the IELSG37 trial

Blood

Zucca E, Ceriani L, Ciccone G, Di Rocco A, Pirosa MC, Kriachok I, Botto B, Balzarotti M MD, Tucci A, Usai SV, Zilioli VR, Pennese E, Arcaini L, Dabrowska-Iwanicka AP, Ferreri AJM, Merli F, Zhao WL, Rigacci L, Cellini C, Hodgson D, Ionescu C, Minoia C, Lucchini E, Spina M, Fosså A, Janikova A, Cwynarski K, Mikhaeel NG, Jerkeman M, Stathis A, Cozens KS, Ielmini N, De Martino I, Walewski J, Trněný M, Cavalli F, Ricardi U, Johnson PWM, Davies AJ, Martelli M

doi: 10.1182/blood.2025028823

Related content